Cassava Sciences : Corporate Presentation – First Quarter 2024

Corporate Overview First Quarter 2024

Forward-Looking Statements & Other Notices

Cassava Sciences is in the business of new drug discovery and development. Our research and development activities are long, complex, costly and involve a high degree of risk. Holders of our common stock should carefully read our Annual Report on Form 10-K in its entirety, including the risk factors therein. Because risk is fundamental to the process of drug discovery and development, you are cautioned to not invest in our publicly traded securities unless you are prepared to sustain a total loss of the money you have invested. Only a small number of research and development programs result in regulatory approval and subsequent commercialization of a product. In addition, our clinical results from earlier-stage clinical trials may not be indicative of full results or results from later-stage or large-scale clinical trials and do not ensure or imply regulatory approval. You should not place undue reliance on our earlier-stage clinical trial results we present or publish.

Simufilam is our investigational drug product candidate. It is not approved by any regulatory authority in any jurisdiction and its safety, efficacy or other desirable attributes, if any, have not been established in patients. Data from our clinical studies to date are all inherently exploratory in nature, should be interpreted with caution and should not be interpreted as clinical evidence of therapeutic safety or benefit for simufilam.

This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, relating to: the design, scope, conduct or intended purpose of our two-year, open-label safety study or our Phase 3 program of simufilam in patients with Alzheimer's disease; the ability of simufilam to provide patients with beneficial drug effects; the apparent ability of simufilam to favor patients with mild Alzheimer's disease; the apparent safety or tolerance of simufilam in our open-label clinical trials; our current expectations regarding timing of clinical data for our Phase 3 studies; any expected clinical results of Phase 3 studies; the treatment of people with Alzheimer's disease dementia; the interim safety or efficacy of simufilam, if any, in people with Alzheimer's disease dementia; any findings or recommendations by the DSMB relating to the interim safety of simufilam in our on-going Phase 3 clinical trials; interim MRI safety data for the Phase 3 program, including ARIA; the risk of current or future findings of treatment-emergent ARIA in our clinical program of simufilam; the suitability of clinical data from our Phase 3 program to support the filing of an NDA; our ability to obtain FDA approval for simufilam, even with a potential NDA filing and positive clinical Phase 3 results and data; comments made by our employees regarding simufilam, drug effect, and the treatment of Alzheimer's disease; and potential benefits, if any, of our product candidates. These statements may be identified by words such as "may," "anticipate," "believe," "could," "expect," "would", "forecast," "intend," "plan," "possible," "potential," and other words and terms of similar meaning.

Such statements are based largely on our current expectations and projections about future events. Such statements speak only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, including, but not limited to, those risks relating to our ability to conduct or complete clinical studies on expected timelines, to demonstrate the specificity, safety, efficacy or potential health benefits of our product candidates, if any, and including those described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent reports filed with the SEC. The foregoing sets forth some, but not all, of the factors that could cause actual results to differ from expectations in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking statements and events discussed in this presentation are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, we disclaim any intention or responsibility for updating or revising any forward-looking statements contained in this presentation. For further information regarding these and other risks related to our business, investors should consult our filings with the SEC, which are available on the SEC's website atwww.sec.gov.

This presentation may also contain statistical data and drug information based on independent sources, industry publications or other publicly available information. We have not independently verified the accuracy or completeness of such data and information. Accordingly, we make no representations as to the accuracy or completeness of such data or information. You are cautioned not to give undue weight to such data. This presentation is solely our responsibility and does not represent the views of the National Institutes of Health or any other government agency, or clinical site investigators, or other third-party.

Introduction to Cassava Sciences

We are a biotechnology company based in Austin, Tx.

We are developing an innovative drug candidate for people with Alzheimer's disease.

Our science is based on stabilizing-but not removing-a critical protein in the brain.

Our lead drug candidate, simufilam, is in Phase 3 clinical testing in patients with Alzheimer's disease.

Cassava Sciences - Senior Management

Years of experience with scientific and drug innovations.

Remi Barbier - Chairman, President & CEO

Michael Zamloot - SVP, Technical Operations

Chris Cook - SVP, General Counsel

Alzheimer's Disease: a Significant Unmet Need

Alzheimer's disease outranks cancer, stroke and heart

attack as most-feared chronic disease by retirees,

according to a study.1

Cassava Sciences sees an opportunity to serve patients,

create value for stakeholders.

Signature of Alois Alzheimer, circa 1915

5

1 Source: "The Four Pillars of the New Retirement", EdwardJones, accessed on-line November 2022.

Ultimately, a Fatal Disease

Alzheimer's disease (AD) is a chronic, progressive neurological disorder.

AD causes memory loss, difficulty speaking & understanding, behavior changes, other issues.

Eventually, the AD patient is unable to perform daily functions.

6 6

Simufilam Is Our Lead Drug Candidate For Alzheimer's1

Simufilam is a novel small molecule (oral) drug.

Our drug targets altered filamin A protein, which is found in the Alzheimer's brain.

➢ Importantly, our drug does not seek to clear amyloid out of the brain.

Cassava Sciences owns exclusive, worldwide rights to simufilam and related technologies, without financialobligations to any third party.

1 Simufilam is an investigational drug that is not approved by any regulatory authority and its safety or efficacy, if any, have not been established.

Science and Basic Research

In-house Discovery/Development Program

<2008 - present

Basic research around neurobiology of Filamin A (FLNA) with academic and other collaborators.

2009

Discovery that altered FLNA links to 7nAChR when A signals.

2017 - present IND filing.

Clinical testing of simufilam.

Mechanism of Action, Simplified

Simufilam targets an altered form of filamin A protein found in the

Alzheimer's brain.

• i. Scaffolding proteins, such as filamin A (FLNA), link other proteins into stable, healthy conformations.

• ii. The AD brain has an altered form of FLNA - Aβ42 binds α7nAChR and recruits FLNA, altering its shape.

• iii. Altered FLNA enables A neurotoxicity - altered FLNA linkage to α7nAChR enables high-affinity binding of Aβ42 for α7nAChR and cell signaling that hyperphosphorylates tau.

• iv. Simufilam disables A neurotoxicity by binding to altered FLNA, restoring its proper shape/function - disrupts its linkage to α7nAChR, stops Aβ42 signaling and tau hyperphosphorylation.

10

Attachments

• Original Link
• Original Document
• Permalink

Disclaimer

Cassava Sciences Inc. published this content on 25 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 March 2024 13:35:03 UTC.